Page 1 of 35

Treatment of Acute Myeloid Leukemia:

Managing the AML Patient When Transplant

is NOT an Option

Harry P. Erba, MD PhD

Professor, Medicine

Director, Leukemia Program

Division of Hematologic Malignancies and Cellular Therapy

Duke University

Durham, NC

Page 2 of 35

Disclosures of Potential Conflicts of Interest

(09/01/2021 to 11/12/2023)

• Speaker Bureau: AbbVie, BMS, Incyte, Jazz, Novartis, Servier

• Consultant: AbbVie, Astellas, BMS, Daiichi Sankyo, Glycomimetics, Incyte,

Jazz, Kura Oncology, Novartis, Pfizer, Servier, Stemline, Sumitomo Pharma

• Contracted Research: AbbVie, ALX Oncology, Amgen, Aptose, Ascentage,

Daiichi Sankyo, Forma, Gilead, Glycomimetics, Immunogen, Jazz, Kura

Oncology, MacroGenics, Novartis, PTC, Sumitomo Pharma

• Other: BMS (Chair, AML Registry Steering Committee), AbbVie (Chair, IRC

for VIALE A and VIALE C), Glycomimetics (Scientific Steering Committee)

Page 3 of 35

The Current AML Treatment Algorithm

AML Dx

Fit (appropriate) for

intensive chemotherapy

Unfit (inappropriate) for

intensive chemotherapy

HMA or LoDAC

HMA/venetoclax

LoDAC/venetoclax

LoDAC/glasdegib

Gemtuzumab ozogamicin

FLT3, IDH1m, IDH2m inhibitors

Induction

chemotherapy ALLOGENEIC

STEM CELL

TRANSPLANT

Consolidation

chemotherapy

CONTINUED THERAPY

Response

CR CR

OBSERVATION OR

MAINTENANCE THERAPY